Principal Investigator:Ganesh Avhad,Swasthiye Clinic and Research Center � NMN

EffePharm LTD, based in Shanghai,  initiated a study in December 2020 to evaluate the anti-aging effects of their NMN formulation (Uthever) and its safety in a double-blind, parallel, randomised controlled clinical trial.  The study was completed in March 2021. The study was carried out on 66 healthy subjects between the ages of 40 and65 years, instructed to take two capsules (each containing 150 mg. of NMN or starch powder) once a day after breakfast for 60 days. At day 30, NAD+/NADH levels in the serum showed an increase of 11.3%, whereas the placebo group showed no change at all. At day 60 of the NAD+/NADH levels increased an additional 38% compared to baseline, against a 14.3% in the placebo group. Additional details were published in the May 2022 issue of Frontiers in Aging